Health Secretary Robert F. Kennedy Jr. has directed the Food and Drug Administration to review the nutrients and other ...

Research news last week included Rocket Pharmaceuticals suffering a setback with its Phase II trial of RP-A501, which ...

The Space Launch System rocket's RS-25 engine was fired up for the “final round of certification testing ahead of production ...

China is developing reusable rockets to launch in 2025 and 2026. See the 'net' technology they will use to catch the booster ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

While an adverse event reported in Intellia’s gene therapy trial was a “non-concern” for analysts, it follows a handful of ...

At Technical.ly’s Builders Conference, lawyers and entrepreneurs each offered blunt advice on how to avoid common early-stage legal errors, from overlooked IP to handshake deals gone wrong.

Paradromics, which directly competes with Elon Musk's Austin-based Neuralink, is looking to build a brain-computer interface ...

Northrop Grumman remains a solid, essential defense contractor, but its stock is overvalued with slow growth. Click here to ...

Regencell's stock soared 17,000% fueled by speculation, despite no revenue or clinical progress. Read why I think the RGC ...

Charlottesville biotech support helps startups like Luminoah and Rivus grow, with the Manning Institute and CvilleBioHub leading the way ...

Meanwhile, Merus, a Netherlands-based cancer cure developer, saw its shares jump after unveiling interim phase 2 data for its experimental antibody petosemtamab in combination with pembrolizumab for ...